JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Real-time continuous glucose monitoring in randomized control trials.

Several recent randomized controlled trials offer firm evidence supporting the efficacy and safety of real-time continuous glucose monitoring (RT-CGM) in type 1 diabetes mellitus (T1DM). Improved metabolic control with significant lowering of glycated hemoglobin (A1C) along with other parameters of glycemia, and without a concomitant increase in hypoglycemia, has been demonstrated. However, poor compliance in adolescents has been a limiting factor in that age group. The potential of RT-CGM of reducing hypoglycemia in well-controlled individuals with T1DM is anticipated but remains to be confirmed. The current high cost of this technology may limit clinical experience in routine clinical settings.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app